Chromadex Corp CS (CDXC) 3.78 $CDXC U.S. FDA issues GRAS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chromadex Corp CS (CDXC) 3.78 $CDXC

U.S. FDA issues GRAS No Objection Letter for NIAGEN(R)
GlobeNewswire - Mon Aug 15, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No Objection Letter, in response to the NIAGEN(R) nicotinamide riboside chloride (NR) GRAS filing, Notice No. GRN 000635.
CDXC: 3.78 (+0.01)

ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period
GlobeNewswire - Thu Aug 11, 3:10PM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today record revenue for the second quarter ended July 2, 2016.
CDXC: 3.78 (+0.01)

Scientists Find Important Clue to Restoring Muscle Function That's Lost as We Age
GlobeNewswire - Wed Aug 10, 5:30AM CDT
-- Published study in mice points to the potential of a form of vitamin B3 referred to as NR to trigger this regenerative process
CDXC: 3.78 (+0.01)

ChromaDex to Report Second Quarter 2016 Financial Results on Thursday, August 11, 2016
GlobeNewswire - Tue Aug 02, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its second quarter 2016 financial results on Thursday, August 11, after the close of the financial markets.
CDXC: 3.78 (+0.01)

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of ChromaDex Corporation And Advises Investors With Losses to Contact the Firm
BusinessWire - Thu Jun 23, 2:14PM CDT
Lundin Law PC announces it is investigating claims against ChromaDex Corporation ("ChromaDex" or the "Company" (Nasdaq: CDXC) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by ChromaDex were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
CDXC: 3.78 (+0.01)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Securities Fraud Violations by Certain Officers and Directors of ChromaDex Corporation
BusinessWire - Tue Jun 21, 5:05PM CDT
Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company" (NASDAQ:CDXC) concerning possible violations of federal securities laws.
CDXC: 3.78 (+0.01)

Lifshitz & Miller Law Firm Announces Investigation of ChromaDex Corporation, CPI Card Group Inc., Electro Rent Corporation, Elizabeth Arden, Inc., Envision Healthcare Holdings, Inc., FEI Company, Polonia Bancorp, Inc., and SciQuest, Inc.
PR Newswire - Tue Jun 21, 12:19PM CDT
ChromaDex Corporation (CDXC)
EVHC: 20.97 (-0.31), RDEN: 13.93 (-0.01), PMTS: 5.00 (+0.13), SQI: 17.75 (unch), CDXC: 3.78 (+0.01), ELRC: 15.50 (+0.01), FEIC: 106.51 (-0.01)

IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against ChromaDex Corporation And Advises Investors With Losses To Contact The Firm
BusinessWire - Mon Jun 20, 7:23PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by ChromaDex Corporation ("ChromaDex" or the "Company" (Nasdaq: CDXC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
CDXC: 3.78 (+0.01)

ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
GlobeNewswire - Tue Jun 07, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.
ABT: 44.14 (-0.10), CDXC: 3.78 (+0.01)

ChromaDex Announces $5.25 Million Registered Direct Offering
GlobeNewswire - Mon Jun 06, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into an agreement with one investor to purchase $5.25 million of the Company's common stock in a registered direct offering. The fees associated with this transaction were minimal as no underwriter or placement agent was used in the offering.
CDXC: 3.78 (+0.01)

University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
GlobeNewswire - Wed Jun 01, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex's nicotinamide riboside (NR), NIAGEN, which is a form of vitamin B3. The results of this study, published in the journal Scientific Reports, demonstrate that NR was successful at reducing fasting and non-fasting blood glucose levels, as well as weight gain, and was protective against sensory neuropathy in these groups.
CDXC: 3.78 (+0.01)

ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
GlobeNewswire - Wed May 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York, N.Y.
CDXC: 3.78 (+0.01)

ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
GlobeNewswire - Wed May 18, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17 Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the Loews Hollywood Hotel in Los Angeles, California.
CDXC: 3.78 (+0.01)

ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
GlobeNewswire - Mon May 16, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing.
CDXC: 3.78 (+0.01)

ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
GlobeNewswire - Thu May 12, 5:30AM CDT
-Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million-
CDXC: 3.78 (+0.01)

ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
GlobeNewswire - Tue May 10, 5:45AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets.
CDXC: 3.78 (+0.01)

Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 42.51 (-0.51), COOL: 3.60 (-0.06), OPK: 9.73 (-0.10), CDXC: 3.78 (+0.01), TEVA: 53.67 (+0.68), MJCO: 5.20 (+0.04)

ChromaDex Corp. (Nasdaq: CDXC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu May 05, 9:00AM CDT
What:
CDXC: 3.78 (+0.01), NDAQ: 70.38 (-0.06)

ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
GlobeNewswire - Thu Apr 28, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York.
CDXC: 3.78 (+0.01)

ChromaDex to Begin Trading on The NASDAQ Capital Market Today
GlobeNewswire - Mon Apr 25, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), formerly (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, today announced that the Company's common stock will be eligible to trade on The NASDAQ Capital Market under the symbol "CDXC" upon the open of the market today.
CDXC: 3.78 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 385

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 430

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Highlights Positive Share Buy-Back Activities

Updated Category News Views 137

Banco Comercial Português: An Overview of Recent Developments Banco Comercial Português, S.A., recognized for its pivotal role in the financial sector, has recently shared insights about its Share Buy-Back Programme. This initiative reflects the bank's commitment to enhancing shareholder value while solidifying its market presence. The interim report detailing the...

Continue Reading
How a $1000 Investment in Texas Instruments Transforms Over 15 Years

Updated Category News Views 135

Understanding the Growth of Texas Instruments Investments Texas Instruments (NASDAQ: TXN) has displayed impressive growth over the past 15 years, outpacing the market by an average of 2.3% annually. This translates to a robust average annual return of 14.17%, reflecting this company's strong position in the semiconductor industry. With a market capitalization now standing...

Continue Reading
Bitdeer Technologies Group's Q4 2024 Financial Overview

Updated Category News Views 204

Bitdeer Technologies Group's Financial Results Analysis Bitdeer Technologies Group (NASDAQ: BTDR), a prominent player in blockchain technology and high-performance computing, has recently unveiled its unaudited financial results for the final quarter of 2024. The announcement sheds light on the company's performance, revealing significant shifts in revenue and expenses...

Continue Reading
NodeAI Revolutionizes Lung Cancer Care with AI Solutions

Updated Category News Views 206

NodeAI's Groundbreaking Achievement in Cancer Diagnostics NodeAI, a pioneering startup based in Hamilton, Ontario, has recently garnered attention for its exceptional advancements in lung cancer diagnostics. The company participated in FACIT's annual pitch competition, known as Falcons' Fortunes, and emerged victorious, earning a prestigious award for its innovative...

Continue Reading
Runway Growth Capital Bolsters Leadership with Rovner

Updated Category News Views 72

A New Era for Runway Growth Capital Alright folks, here's the scoop for anyone tracking the moves in the growth lending space: Michael Rovner, with his hefty 30-year career in the financial sector, is now taking on the role of Co-Chief Executive Officer and Co-Chief Investment Officer at Runway Growth Capital. This guy's a veteran, no doubt, having navigated the overlaps...

Continue Reading